➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Mallinckrodt
Express Scripts
Moodys
AstraZeneca

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RELENZA

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Relenza

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00784784 ↗ Zanamivir Versus Trivalent Split Virus Influenza Vaccine Completed GlaxoSmithKline Phase 3 2008-11-01 This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers. The pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers.
NCT00784784 ↗ Zanamivir Versus Trivalent Split Virus Influenza Vaccine Completed Mount Sinai Hospital, Canada Phase 3 2008-11-01 This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers. The pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers.
NCT00867139 ↗ TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients Completed Fred Hutchinson Cancer Research Center Phase 1/Phase 2 2009-03-01 The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Relenza

Condition Name

Condition Name for Relenza
Intervention Trials
Influenza, Human 4
Influenza 4
Bronchospasm 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Relenza
Intervention Trials
Influenza, Human 7
Respiration Disorders 1
Respiratory Tract Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Relenza

Trials by Country

Trials by Country for Relenza
Location Trials
United States 26
China 8
Australia 5
Canada 5
Mexico 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Relenza
Location Trials
Texas 1
Illinois 1
Wisconsin 1
Washington 1
Alabama 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Relenza

Clinical Trial Phase

Clinical Trial Phase for Relenza
Clinical Trial Phase Trials
Phase 3 3
Phase 1/Phase 2 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Relenza
Clinical Trial Phase Trials
Completed 7
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Relenza

Sponsor Name

Sponsor Name for Relenza
Sponsor Trials
GlaxoSmithKline 5
National Institute of Allergy and Infectious Diseases (NIAID) 1
Johns Hopkins Bloomberg School of Public Health 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Relenza
Sponsor Trials
Other 6
Industry 5
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Medtronic
McKinsey
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.